Standout Papers

Renal sympathetic denervation in pati... 1986 2026 1999 2012 1.4k
  1. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial (2010)
    Murray Esler, Henry Krum et al. The Lancet
  2. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study (2009)
    Henry Krum, Markus P. Schlaich et al. The Lancet
  3. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. (1986)
    Gregory J. Hasking, Murray Esler et al. Circulation
  4. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions (1990)
    Murray Esler, Garry Jennings et al. Physiological Reviews
  5. Adverse consequences of high sympathetic nervous activity in the failing human heart (1995)
    David M. Kaye, Jeffrey Lefkovits et al. Journal of the American College of Cardiology
  6. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. (1988)
    Murray Esler, Garry Jennings et al. Hypertension
  7. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study (2013)
    Henry Krum, Markus P. Schlaich et al. The Lancet
  8. The Sympathetic Nervous System Alterations in Human Hypertension (2015)
    Guıdo Grassı, Allyn L. Mark et al. Circulation Research
  9. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension (2011)
    Felix Mahfoud, Markus P. Schlaich et al. Circulation
  10. Mild High-Renin Essential Hypertension (1977)
    Murray Esler, Stevo Julius et al. New England Journal of Medicine
  11. The human sympathetic nervous system: its relevance in hypertension and heart failure (2012)
    Gianfranco Parati, Murray Esler European Heart Journal

Immediate Impact

7 by Nobel laureates 4 from Science/Nature 72 standout
Sub-graph 1 of 15

Citing Papers

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial
2022 Standout
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
2020 Standout
14 intermediate papers

Works of Murray Esler being referenced

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
2020
Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation
2004
and 20 more

Author Peers

Author Last Decade Papers Cites
Murray Esler 22752 4713 4445 4703 446 31.9k
Guıdo Grassı 23211 4827 5120 3799 696 31.3k
Thomas G. Pickering 23583 6280 2850 4728 418 35.5k
Alberto Zanchetti 33634 6965 10242 2898 819 44.3k
Garry Jennings 13098 2873 2824 3165 420 21.0k
Gavin Lambert 10416 2608 2215 4150 401 18.7k
David S. Goldstein 8023 7563 4680 4250 476 29.7k
David M. Kaye 14987 3927 1763 4757 606 25.9k
Douglas R. Seals 16711 2552 1865 10808 437 33.2k
Krzysztof Narkiewicz 12018 2457 2620 5163 378 19.0k
Allyn L. Mark 11284 2910 1964 7097 190 19.8k

All Works

Loading papers...

Rankless by CCL
2026